Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

INTRODUCTION: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these patients. METHODS: Outcomes after CCRT (2010–2019) or CCRT followed by durvalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Wang, Xu, Ting, Wu, Lirong, Lopez, Pablo B., Grassberger, Clemens, Ellsworth, Susannah G., Mohan, Radhe, Hobbs, Brian P., Blumenschein, George R., Tu, Janet, Altan, Mehmet, Lee, Percy, Liao, Zhongxing, Lin, Steven H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449658/
https://www.ncbi.nlm.nih.gov/pubmed/36089921
http://dx.doi.org/10.1016/j.jtocrr.2022.100391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449658/
https://www.ncbi.nlm.nih.gov/pubmed/36089921
http://dx.doi.org/10.1016/j.jtocrr.2022.100391

Ejemplares similares